These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 30321546)

  • 1. Physiologically Based Modeling of the Pharmacokinetics of "Catch-and-Release" Anti-Carcinoembryonic Antigen Monoclonal Antibodies in Colorectal Cancer Xenograft Mouse Models.
    Polli JR; Engler FA; Balthasar JP
    J Pharm Sci; 2019 Jan; 108(1):674-691. PubMed ID: 30321546
    [TBL] [Abstract][Full Text] [Related]  

  • 2. "Catch-and-Release" Anti-Carcinoembryonic Antigen Monoclonal Antibody Leads to Greater Plasma and Tumor Exposure in a Mouse Model of Colorectal Cancer.
    Engler FA; Polli JR; Li T; An B; Otteneder M; Qu J; Balthasar JP
    J Pharmacol Exp Ther; 2018 Jul; 366(1):205-219. PubMed ID: 29735609
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Application of PBPK modeling to predict monoclonal antibody disposition in plasma and tissues in mouse models of human colorectal cancer.
    Abuqayyas L; Balthasar JP
    J Pharmacokinet Pharmacodyn; 2012 Dec; 39(6):683-710. PubMed ID: 23184417
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cell Penetrating Peptides Conjugated to Anti-Carcinoembryonic Antigen "Catch-and-Release" Monoclonal Antibodies Alter Plasma and Tissue Pharmacokinetics in Colorectal Cancer Xenograft Mice.
    Polli JR; Balthasar JP
    Bioconjug Chem; 2022 Aug; 33(8):1456-1466. PubMed ID: 35867869
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Application of a catenary PBPK model to predict the disposition of "catch and release" anti-PCSK9 antibodies.
    Glassman PM; Balthasar JP
    Int J Pharm; 2016 May; 505(1-2):69-78. PubMed ID: 27041125
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Target mediated disposition of T84.66, a monoclonal anti-CEA antibody: application in the detection of colorectal cancer xenografts.
    Urva SR; Balthasar JP
    MAbs; 2010; 2(1):67-72. PubMed ID: 20081377
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Physiologically based pharmacokinetic model for T84.66: a monoclonal anti-CEA antibody.
    Urva SR; Yang VC; Balthasar JP
    J Pharm Sci; 2010 Mar; 99(3):1582-600. PubMed ID: 19774657
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Towards a platform PBPK model to characterize the plasma and tissue disposition of monoclonal antibodies in preclinical species and human.
    Shah DK; Betts AM
    J Pharmacokinet Pharmacodyn; 2012 Feb; 39(1):67-86. PubMed ID: 22143261
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetic mAb-mAb interaction: anti-VEGF mAb decreases the distribution of anti-CEA mAb into colorectal tumor xenografts.
    Abuqayyas L; Balthasar JP
    AAPS J; 2012 Sep; 14(3):445-55. PubMed ID: 22528507
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of Different Selectivity between Soluble and Membrane-bound Forms of Carcinoembryonic Antigen (CEA) on the Target-mediated Disposition of Anti-CEA Monoclonal Antibodies.
    Iwano J; Shinmi D; Masuda K; Murakami T; Enokizono J
    Drug Metab Dispos; 2019 Nov; 47(11):1240-1246. PubMed ID: 31533926
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sorafenib Decreases Tumor Exposure to an Anti-carcinoembryonic Antigen Monoclonal Antibody in a Mouse Model of Colorectal Cancer.
    Thomas VA; Balthasar JP
    AAPS J; 2016 Jul; 18(4):923-32. PubMed ID: 27029796
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dynamic Contrast-Enhanced Magnetic Resonance Imaging for the Prediction of Monoclonal Antibody Tumor Disposition.
    Bordeau BM; Polli JR; Schweser F; Grimm HP; Richter WF; Balthasar JP
    Int J Mol Sci; 2022 Jan; 23(2):. PubMed ID: 35054865
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Physiologically-based pharmacokinetic modeling to predict the clinical pharmacokinetics of monoclonal antibodies.
    Glassman PM; Balthasar JP
    J Pharmacokinet Pharmacodyn; 2016 Aug; 43(4):427-46. PubMed ID: 27377311
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 124I-labeled engineered anti-CEA minibodies and diabodies allow high-contrast, antigen-specific small-animal PET imaging of xenografts in athymic mice.
    Sundaresan G; Yazaki PJ; Shively JE; Finn RD; Larson SM; Raubitschek AA; Williams LE; Chatziioannou AF; Gambhir SS; Wu AM
    J Nucl Med; 2003 Dec; 44(12):1962-9. PubMed ID: 14660722
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enhancement of colorectal tumor targeting using a novel biparatopic monoclonal antibody against carcinoembryonic antigen in experimental radioimmunoguided surgery.
    Kim JC; Roh SA; Koo KH; Ryu JH; Hong HK; Oh SJ; Ryu JS; Kim HJ; Bodmer WF
    Int J Cancer; 2002 Feb; 97(4):542-7. PubMed ID: 11802220
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Scale-up of a physiologically-based pharmacokinetic model to predict the disposition of monoclonal antibodies in monkeys.
    Glassman PM; Chen Y; Balthasar JP
    J Pharmacokinet Pharmacodyn; 2015 Oct; 42(5):527-40. PubMed ID: 26364301
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PET imaging of colorectal cancer in xenograft-bearing mice by use of an 18F-labeled T84.66 anti-carcinoembryonic antigen diabody.
    Cai W; Olafsen T; Zhang X; Cao Q; Gambhir SS; Williams LE; Wu AM; Chen X
    J Nucl Med; 2007 Feb; 48(2):304-10. PubMed ID: 17268029
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combination of antibody targeting and PTD-mediated intracellular toxin delivery for colorectal cancer therapy.
    Shin MC; Zhang J; Ah Min K; Lee K; Moon C; Balthasar JP; Yang VC
    J Control Release; 2014 Nov; 194():197-210. PubMed ID: 25204286
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting and therapy of carcinoembryonic antigen-expressing tumors in transgenic mice with an antibody-interleukin 2 fusion protein.
    Xu X; Clarke P; Szalai G; Shively JE; Williams LE; Shyr Y; Shi E; Primus FJ
    Cancer Res; 2000 Aug; 60(16):4475-84. PubMed ID: 10969795
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Factors influencing the pharmacokinetics, dosimetry, and diagnostic accuracy of radioimmunodetection and radioimmunotherapy of carcinoembryonic antigen-expressing tumors.
    Behr TM; Sharkey RM; Juweid MI; Dunn RM; Ying Z; Zhang CH; Siegel JA; Gold DV; Goldenberg DM
    Cancer Res; 1996 Apr; 56(8):1805-16. PubMed ID: 8620497
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.